Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease.  We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies.  Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Our most advanced program is directed towards development of first-in-class agents that modulate the O-GlcNAcase (OGA) enzyme as a disease-modifying therapy for treatment of Alzheimer’s disease and other neurodegenerative disorders; this program is partnered with Merck.  As part of its pipeline, Alectos is also advancing discovery-stage programs in oncology and Parkinson’s disease.

Alectos Engages As Industry Partner in the Canadian Glycomics Network (GlycoNet)

Feb 17, 2015 – Alectos today announced its support as an industry partner in the new Canadian Glycomics Network (GlycoNet), unveiled this [...]

Alectos Announces Preclinical Results in TAPP Mouse Model of Alzheimer’s Disease

Oct. 26, 2014 – Alectos today announced publication of preclinical studies showing that pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and [...]

Alectos Supports NSERC Funding for Prof. M.J. Boulanger at UVic

Oct 6, 2014 – Alectos today announced its support for NSERC funding for the group of Prof. M.J. Boulanger at the University [...]

Alectos Announces Preclinical Data for Novel Cancer Metabolism Target

May 22, 2014 – Alectos today announced publication of preclinical studies showing that both knockdown and pharmacological inhibition of O-GlcNAc transferase (OGT) [...]

Alectos Supports NSERC Funding for Prof. B.M. Pinto at SFU

July 16, 2012 – Alectos today announced its support for NSERC funding for the group of Prof. B.M. Pinto at Simon Fraser [...]